Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
CA 2426785 A1 · Owner: Allergan, Inc. · Inventors: Posner, Mari F.; Burk, Robert M.; Holoboski, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: wherein the hatched segment represents an .alpha. bonds the solid triangle represents a .beta. bond the wavy segments represent a , .alpha. or .beta. bond dashed lines represent a double bond or a single bond R3 is heteroaryl or a substituted heteroaryl radical R1 and R2 are , independently selected from the group consisting of hydrogen or a lower alkyl radical having up to six carbon atoms, or a lower acyl radical having up to six carbon …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 26, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 26, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 26, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.